Posted inUncategorized
In Vivo Drug Lead Studies for Prostate Cancer Treatment – IMMUNOLOGY Completes
HBC Immunology is proud to announce that its prostate cancer treatment xenograft study with its lead peptide FT002a was completed successfully. This was done in combination with the standard-of-care hormonal-targeting…
